ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. More Details
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has ScandiDos's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SDOS has not had significant price volatility in the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: SDOS underperformed the Swedish Medical Equipment industry which returned 15.7% over the past year.
Return vs Market: SDOS underperformed the Swedish Market which returned 13.4% over the past year.
Price Volatility Vs. Market
How volatile is ScandiDos's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StWhen Will ScandiDos AB (publ) (STO:SDOS) Become Profitable?
4 months ago | Simply Wall StThe ScandiDos (STO:SDOS) Share Price Is Down 58% So Some Shareholders Are Wishing They Sold
6 months ago | Simply Wall StHere's Why We're Not Too Worried About ScandiDos's (STO:SDOS) Cash Burn Situation
Is ScandiDos undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SDOS (SEK2.84) is trading below our estimate of fair value (SEK10.11)
Significantly Below Fair Value: SDOS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SDOS is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: SDOS is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SDOS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SDOS is good value based on its PB Ratio (2.6x) compared to the SE Medical Equipment industry average (4.5x).
How is ScandiDos forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SDOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: SDOS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SDOS's is expected to become profitable in the next 3 years.
Revenue vs Market: SDOS's revenue (14.5% per year) is forecast to grow faster than the Swedish market (3.2% per year).
High Growth Revenue: SDOS's revenue (14.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SDOS's Return on Equity is forecast to be low in 3 years time (17.5%).
How has ScandiDos performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SDOS is currently unprofitable.
Growing Profit Margin: SDOS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SDOS is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare SDOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SDOS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).
Return on Equity
High ROE: SDOS has a negative Return on Equity (-23.78%), as it is currently unprofitable.
How is ScandiDos's financial position?
Financial Position Analysis
Short Term Liabilities: SDOS's short term assets (SEK41.0M) exceed its short term liabilities (SEK28.5M).
Long Term Liabilities: SDOS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SDOS's debt to equity ratio (3.9%) is considered satisfactory.
Reducing Debt: SDOS's debt to equity ratio has reduced from 6.4% to 3.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SDOS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SDOS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is ScandiDos's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SDOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SDOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SDOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SDOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SDOS's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gustaf Piehl (42 yo)
Mr. Gustaf Piehl serves as Chief Executive Officer at ScandiDos AB (publ) since September 2020. He Gustaf has many years of experience in the radiation therapy industry after holding a number of different ...
|Technical Manager||0.083yr||kr1.99m||no data|
|Deputy CEO & Director||5.75yrs||kr1.23m||no data|
|Chief Executive Officer||0.083yr||no data||no data|
|Chief Financial Officer||8.75yrs||no data||no data|
|Marketing Manager||4yrs||no data||no data|
|Vice President of Sales||1.17yrs||no data||no data|
Experienced Management: SDOS's management team is considered experienced (2.6 years average tenure).
|Deputy CEO & Director||5.75yrs||kr1.23m||no data|
|Director||no data||kr100.00k||no data|
|Chairman of the Board||5.75yrs||kr250.00k||no data|
Experienced Board: SDOS's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ScandiDos AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: ScandiDos AB (publ)
- Ticker: SDOS
- Exchange: OM
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr118.987m
- Shares outstanding: 41.46m
- Website: https://scandidos.com
Number of Employees
- ScandiDos AB (publ)
- Uppsala Science Park
- 751 83
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SDOS||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Apr 2014|
|2FV||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Apr 2014|
ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family soluti ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 21:25|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.